Calendario›MIST›The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.
The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.
Ensayo de Milestone Pharmaceuticals Inc. en Paroxysmal Supraventricular Tachycardia (PSVT) (del registro, en inglés).
- Fase
- no aplica
- Estado
- Interrumpido
- Participantes
- 354
- Centros
- 1
- Fin del objetivo primario
- mar 2020
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en oct 2017.
Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Termination due to lack of adequate enrollment».
De principio a fin
- Empieza el ensayo (oct 2017)
- Lectura de resultados mar 2020 (real)
- Hoy
Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.
Qué mide
Patient Reported Frequency of Recurring PSVT Episodes Using a Patient-Directed Survey Developed by Milestone Pharmaceuticals. (Baseline, then every three months for up to 10 years) (del registro, en inglés)
Qué se prueba
Se pone en marcha un registro multinacional, de momento con datos que introducen directamente los propios pacientes.
Lo que dice el documentoa multinational registry, The PSVT Place Registry (www.PSVTPlaceRegistry.com), is being implemented and will be initially comprised of data entered directly by patients.
Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroParoxysmal supraventricular tachycardia (PSVT) is a sporadic, sudden, and recurring tachycardia that is caused by an altered electrical conductivity in the heart. It causes palpitations and a rapid heart rate, which may induce fear in the patient and negatively impact the patient's quality of life. Therefore, most patients experience not only physical symptoms of PSVT, but also dramatic psychological burdens. As PSVT drug development efforts advance, it has become increasingly important to document the impact of PSVT in a systematic way, in terms of the disease natural history and clinical characteristics of PSVT episodes, as well as the psychological impact of the condition as reported by patients over time. In order to meet the needs for ongoing, systematic data collection on PSVT, a multinational registry, The PSVT Place Registry (www.PSVTPlaceRegistry.com), is being implemented and will be initially comprised of data entered directly by patients. The long-term registry is designed with a participant-focused approach to enable continuity of data collection and minimization of impact from changes of participants' health care providers. The registry may be expanded at a later time to include physician-reported data. The information from the registry is planned to be a resource for participants with PSVT, their families and support networks, their doctors, and the research community to better understand PSVT-related symptoms and awareness, PSVT diagnoses, patient self-management, medical treatments for PSVT, and impact of PSVT on quality of life from the patient perspective.
Sigue a MIST y recibe cada mañana en tu correo lo que haya presentado ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.
Más ensayos de MIST
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Etripamil NS | Fase 2 | Reclutando pacientes | jun 2027 (prevista) |
| Etripamil · ReVeRA-301 | Fase 3 | Reclutando pacientes | dic 2028 (prevista) |
| Etripamil NS 70 mg | Fase 3 | Completado | abr 2026 (real) |
| Etripamil | Fase 2 | Completado | ago 2023 (real) |
| Etripamil NS | Fase 3 | Completado | ene 2023 (real) |
| Etripamil · NODE-301 | Fase 3 | Interrumpido | ene 2023 (real) |
Todos los de MIST, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT03353610), actualizada en dic 2020.